These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 29338958)

  • 21. Reporting guidelines for economic studies.
    Mason J; Drummond M
    Health Econ; 1995; 4(2):85-94. PubMed ID: 7613600
    [No Abstract]   [Full Text] [Related]  

  • 22. Recommendations of the Panel on Cost-effectiveness in Health and Medicine.
    Weinstein MC; Siegel JE; Gold MR; Kamlet MS; Russell LB
    JAMA; 1996 Oct; 276(15):1253-8. PubMed ID: 8849754
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness analysis in heart disease, Part I: General principles.
    Kupersmith J; Holmes-Rovner M; Hogan A; Rovner D; Gardiner J
    Prog Cardiovasc Dis; 1994; 37(3):161-84. PubMed ID: 7972851
    [No Abstract]   [Full Text] [Related]  

  • 24. Policy ... research that rings true.
    Hosp Health Netw; 1996 Oct; 70(19):13. PubMed ID: 8885294
    [No Abstract]   [Full Text] [Related]  

  • 25. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule?
    Braithwaite RS; Meltzer DO; King JT; Leslie D; Roberts MS
    Med Care; 2008 Apr; 46(4):349-56. PubMed ID: 18362813
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A proposal to solve the comparability problem in cost-utility analysis.
    Bleichrodt H; Herrero C; Pinto JL
    J Health Econ; 2002 May; 21(3):397-403. PubMed ID: 12022265
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Thresholds in cost-effectiveness analysis--more of the story.
    Laufer F
    Value Health; 2005; 8(1):86-7. PubMed ID: 15841899
    [No Abstract]   [Full Text] [Related]  

  • 28. Costing and perspective in published cost-effectiveness analysis.
    Neumann PJ
    Med Care; 2009 Jul; 47(7 Suppl 1):S28-32. PubMed ID: 19536023
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness analysis: can we reduce variability in costing methods?
    Adam T; Koopmanschap MA; Evans DB
    Int J Technol Assess Health Care; 2003; 19(2):407-20. PubMed ID: 12862197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidelines for pharmacoeconomic studies. Recommendations from the panel on cost effectiveness in health and medicine. Panel on cost Effectiveness in Health and Medicine.
    Siegel JE; Torrance GW; Russell LB; Luce BR; Weinstein MC; Gold MR
    Pharmacoeconomics; 1997 Feb; 11(2):159-68. PubMed ID: 10172935
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A conversation with E. Andrew Balas, M.D.
    Balas EA
    Manag Care; 1998 Feb; 7(2):37-41. PubMed ID: 10178884
    [No Abstract]   [Full Text] [Related]  

  • 32. A proposed model for conducting institutional-specific cost-effectiveness analysis: a case study of lipid-lowering agents.
    Hakim Z; Pierson JF; Pathak DS
    Pharm Pract Manag Q; 1996 Apr; 16(1):79-97. PubMed ID: 10157744
    [No Abstract]   [Full Text] [Related]  

  • 33. A review of the use of health status measures in economic evaluation.
    Brazier J; Deverill M; Green C; Harper R; Booth A
    Health Technol Assess; 1999; 3(9):i-iv, 1-164. PubMed ID: 10392311
    [No Abstract]   [Full Text] [Related]  

  • 34. Willingness-to-pay (WTP): the new-old kid on the economic evaluation block.
    Gafni A
    Can J Nurs Res; 2001 Jun; 33(1):59-64. PubMed ID: 11928155
    [No Abstract]   [Full Text] [Related]  

  • 35. Forget CEA (cost effectiveness analysis). Use DEA (data envelopment analysis)!
    Rosenberg D
    J Health Hum Resour Adm; 1991; 14(1):109-12. PubMed ID: 10115636
    [No Abstract]   [Full Text] [Related]  

  • 36. Use of pharmacoeconomics in prescribing research. Part 4: is cost-utility analysis a useful tool?
    Brinsmead R; Hill S
    J Clin Pharm Ther; 2003 Aug; 28(4):339-46. PubMed ID: 12911687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Challenges for cost-effectiveness research.
    Weinstein MC
    Med Decis Making; 1986; 6(4):194-8. PubMed ID: 3095604
    [No Abstract]   [Full Text] [Related]  

  • 38. Fair and reasonable judgments of cost-effectiveness of medicines.
    Olson LG; Hill SR
    Trends Pharmacol Sci; 2014 Dec; 35(12):628-9. PubMed ID: 25441932
    [No Abstract]   [Full Text] [Related]  

  • 39. Theory and methods of economic evaluation of health care.
    Johannesson M
    Dev Health Econ Public Policy; 1996; 4():1-245. PubMed ID: 10158916
    [No Abstract]   [Full Text] [Related]  

  • 40. Accounting for the missing opportunity costs in incremental cost-outcome analysis.
    Oliver A
    Appl Health Econ Health Policy; 2002; 1(4):191-6. PubMed ID: 14619248
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.